Ovarian cancer survivors who live for 10 or more years comprise a heterogeneous patient population with and without recurrent disease.
Long-term survivors may have suboptimal cytoreduction or short platinum free intervals.
BRCA1 and BRCA2 germline mutations appear common among long-term survivors.